Therapeutic drug monitoring (TDM)

CPD Bulletin Clinical Biochemistry

Volumn 9, Issue 1, 2008, Pages 3-21

  Flanagan, Robert J ^a   Brown, Nigel W ^a   Whelpton, Robin ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Digoxin; Lithium; Pharmacokinetics; Psychoactive drugs

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CAFFEINE; CARBAMAZEPINE; CHLOROQUINE; CLOZAPINE; DIGOXIN; FLUOROURACIL; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; ISONIAZID; LITHIUM; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PSYCHOTROPIC AGENT; QUININE; RIFAMPICIN; SALBUTAMOL; SALICYLIC ACID DERIVATIVE; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

AGRANULOCYTOSIS; ANALYTIC METHOD; AREA UNDER THE CURVE; BIOLOGICAL ACTIVITY; BIPOLAR DISORDER; BLINDNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL CHEMISTRY; CLINICAL DECISION MAKING; COMA; CONFUSION; DIARRHEA; DISORIENTATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; GAS CHROMATOGRAPHY; GASTROINTESTINAL SYMPTOM; HAND TREMOR; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MALARIA; MASS SPECTROMETRY; MUSCLE DISEASE; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEWBORN APNEA; NYSTAGMUS; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; POINT OF CARE TESTING; POLYURIA; QUALITY CONTROL; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; THIRST; TOTAL QUALITY MANAGEMENT; UNSPECIFIED SIDE EFFECT; VERTIGO; VISUAL DISORDER; VOMITING;

EID: 66149163328     PISSN: 13678930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Schumacher GE, Barr JT. Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics. Clin Chem 1998; 44: 370-4.
2. Hallworth MJ, Watson ID. Therapeutic Drug Monitoring & Laboratory Medicine. London: ACB Venture Publications 2008.
3. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2001; 52 Suppl 1: 45S-54S.
4. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36(2 Suppl): 396S-403S.
5. NPIS/ACB (National Poisons Information Service/Association of Clinical Biochemists). Laboratory analyses for poisoned patients: joint position paper. Ann Clin Biochem 2002; 39: 328-39).
6. Sato M, Chida K, Suda T, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother 2006; 12: 185-9.
7. Richens A, Dunlop A. Serum-phenytoin levels in management of epilepsy. Lancet 1975; 2: 247-8.
8. Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med 1999; 123: 822-3.
9. Leonard RF, Knott PJ, Rankin GO, et al. Phenytoin-salicylate interaction. Clin Pharmacol Ther 1981; 29: 56-60.
10. Karppi J, Akerman KK, Parviainen M. Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM). Clin Chem Lab Med 2000; 38: 313-20.
11. Croes K, McCarthy PT, Flanagan RJ. Simple and rapid HPLC of quinine, hydroxychloroquine, chloroquine, and desethylchloroquine in serum, whole blood, and filter-paper adsorbed dry blood. J Analyt Toxicol 1994; 18: 255-60.
12. Schramm W, Smith RH, Craig PA, et al. Determination of free progesterone in an ultrafiltrate of saliva collected in situ. Clin Chem 1990; 36: 1488-93.
13. Schramm W, Annesley TM, Siegel GJ, et al. Measurement of phenytoin and carbamazepine in an ultrafiltrate of saliva. Ther Drug Monit 1991; 13: 452-60.
14. Schramm W, Pomerleau OF, Pomerleau CS, et al. Cotinine in an ultrafiltrate of saliva. Prev Med 1992; 21: 63-73.
15. Porter WH, Hanver VM, Bush BA. Effects of protein concentrations on the determination of digoxin in serum by fluorescence polarisation immunoassay. Clin Chem 1984; 39: 1826-9.
16. Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001; 38: 376-85. Erratum: 2001; 38: 731.
17. Tzou MC, Reuning RH, Sams RA. Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease. Clin Pharmacol Ther 1997; 61: 429-41.
18. Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol 2002; 118: 132-40.
19. Berendes E, Cullen P, Van Aken H, et al. Endogenous glycosides in critically ill patients. Crit Care Med 2003; 31: 1331-7.
20. Ijiri Y, Hayahi T, Ogihara T, et al. Increased digitalis-like immunoreactive substances in neonatal plasma measured using fluorescence polarization immunoassay. J Clin Pharm Ther 2004; 29: 565-71.
21. Ijiri Y, Hayashi T, Kamegai H, et al. Digitalis-like immunoreactive substances in maternal and umbilical cord plasma: a comparative sensitivity study of fluorescence polarization immunoassay and microparticle enzyme immunoassay. Ther Drug Monit 2003; 25: 234-9.
22. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 2002; 48: 507-16.
23. Brubacher JR, Hoffman RS, Kile T. Toad venom poisoning: failure of a monoclonal digoxin immunoassay to cross-react with the cardioactive steroids. J Toxicol Clin Toxicol 1996; 34: 529-30.
24. Panesar NS, Chan KW, Law LK. Changing characteristics of the TDx digoxin II assay in detecting bufadienolides in a traditional Chinese medicine: for better or worse? Ther Drug Monit 2005; 27: 677-9.
25. Miller JJ, Straub RW Jr, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit 1996; 18: 65-72.
26. Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004; 27: 1115-33.
27. http://www.nacb.org/lmpg/poct/POCT_LMPG_final_rev41706.pdf, accessed 20 September 2007.
28. http://www.iso.org/iso/isot_analogue/catalogue_tc/ catalogue_detail.htm?csnumber=35173, accessed 20 September 2007.
29. Glazer WM, Sonnenberg JG, Reinstein MJ, et al. A novel, point-of-care test for lithium levels: description and reliability. J Clin Psychiatr 2004; 65: 652-5.
30. Asmus MJ, Milavetz G, Teresi ME, et al. Evaluation of a noninstrumented disposable method for quantifying serum theophylline concentrations. Pharmacotherapy 1998; 18: 30-4.
31. Iwasaki S, Yamakage M, Satoh J, et al. Perioperative evaluation of a kit for simplified measurement of blood theophylline concentration (Accumeter Theophylline). Masui 2005; 54: 1385-91 [Japanese, English abstract].
32. Kratzsch C, Peters FT, Kraemer T, et al. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 2003; 38: 283-95.
33. http://www.iso.ch/iso/en/iso9000-14000/index.html, accessed 10 October 2007.
34. FDA/CDER (Food and Drug Administration/Center for Drug Evaluation and Research) Guidance for industry. Bioanalytical method validation, 2001. (http://www.fda.gov/cder/guidance/4252fnl.htm, accessed 27 August 2007).
35. Clinical and Laboratory Standards Institute. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. Edition 2. Document EP05-A 2, 2004 (http://webstore.ansi.org/ ansidocstore/product.asp?sku=EP05%2DA2, accessed 27 August 2007).
36. Peters FT, Jung J, Kraemer T, et al. Fast, simple, and validated gas chromatographic-mass spectrometric assay for quantification of drugs relevant to diagnosis of brain death in human blood plasma samples. Ther Drug Monit 2005; 27: 334-44.
37. Wilson JF. External quality assessment schemes for toxicology. Forensic Sci Int 2002; 128: 98-103.
38. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95: 1771-83.
39. Kwong TC, Baum J. Monitoring of anti-inflammatory drugs. Clin Lab Med 1987; 7: 687-97.
40. White S, Wong SH. Standards of laboratory practice: analgesic drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44: 1110-23.
41. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2: 334-9.
42. Natarajan G, Botica ML, Thomas R, et al. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007; 119: 936-40.
43. Patsalos PN. Anti-epileptic drug interactions: a clinical guide. Guildford: Surrey: Clarius, 2005.
44. Tomson T, Dahl ML, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev 2007; 1: CD002216.
45. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-75.
46. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007; 377: 1-13.
47. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998; 31: 91-9.
48. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet 2005; 44: 407-16.
49. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42: 1228-55.
50. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. Edition 9. London: Informa Healthcare, 2007.
51. Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatr 2006; 163: 272-5.
52. Breckenridge AM, Winstanley PA. Clinical pharmacology and malaria. Ann Trop Med Parasitol 1997; 91: 727-33.
53. Savarino A, Gennero L, Sperber K, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001; 20: 131-5.
54. Crowley RK, Fitzpatrick FM, Solanki D, et al. Vancomycin administration: the impact of multidisciplinary interventions. J Clin Pathol 2007; 60: 1155-9.
55. Darley ES, MacGowan AP. The use and therapeutic drug monitoring of teicoplanin in the UK. Clin Microbiol Infect 2004; 10: 62-9.
56. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
57. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28: 468-73.
58. Slish JC, Catanzaro LM, Ma Q, et al. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des 2006; 12: 1129-45.
59. Wertheimer BZ, Freedberg KA, Walensky RP, et al. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials 2006; 7: 59-69.
60. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388-400.
61. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16: 253-62.
62. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996; 18: 328-34.
63. Sidwell A, Barclay M, Begg E, et al. Digoxin therapeutic drug monitoring: an audit and review. N Z Med J 2003; 116: U708.
64. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52 Suppl 1: 21S-34S.
65. Till JA, Shinebourne EA, Rowland E, et al. Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. Br Heart J 1989; 62: 133-9.
66. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330-50; erratum: Clin Ther 2002; 24: 1223.
67. Brown NW, Gonde CE, Adams JE, et al. Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem 2005; 51: 586-92.
68. Mitchell PB. Therapeutic drug monitoring of non-tricyclic antidepressant drugs. Clin Chem Lab Med 2004; 42: 1212-8.
69. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22: 143-54.
70. Flanagan RJ. TDM of antipsychotics. CPD Bull Clin Biochem 2006; 7: 3-18.
71. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2004; 11: 279-96.
72. Hiemke C, Dragicevic A, Grunder G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-60.
73. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70-8.